About Us
- Overview
- History
- Mission
- Team
- Contact Us
Our Science
- Our FoCus
- Our Publications
Pipeline
Partnerships
Press Release
- Press Release
- Media Coverage
Join Us
Legal Notice
Privacy Policy

Executive Director, DMPK

Products Blogs

Fengmin Xi,Ph.D.

Dr. Fengmin Xi joined InxMed in March 2023 and currently serves as DMPK Executive Director. Fengmin has more than 10 years of R&D experience in DMPK, toxicology, and medicinal chemistry, additionally, along with rich investment and financing skills in biotechnology. He was previously employed in a biotech boutique investment bank, HollyHigh, and engaged in investment and financing for biotech and CXO companies. Prior to that, he worked for WuXi AppTec (603259. SH/2359.HK) and Medicilon (688202. SH) in clinical bioanalysis, preclinical DMPK, and toxicology. He held a Ph.D. in medicinal chemistry at Peking Union Medical College and Tsinghua University.

Latest Products

Shuang Xie M.D.,Ph.D.

Rangrong Li

Baoyuan Zhang Ph.D.

Yanan Liu,Ph.D.

Yi Huang Ph.D.

Yi Ren

Shiqiang Lu Ph.D.

Liyuan Liu

Fengmin Xi,Ph.D.

Zaiqi Wang M.D.,Ph.D.

Latest Blogs

InxMed and Chugai Enter into a Worldwide License Agreement for　SPYK04, a RAF-MEK Molecular Glue

InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation

Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRASG12C Mutation

Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 tria

Aug，2025

QUICK LINKS

About Us
- Overview
- History
- Mission
- Team
- Contact Us
Our Science
- Our FoCus
- Our Publications
Pipeline
Partnerships
Press Release
- Press Release
- Media Coverage
Join Us
Legal Notice
Privacy Policy

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

MESSAGE

SEO